Edmond DE Rothschild Holding S.A. Invests $12.11 Million in Biogen Inc. $BIIB

Edmond DE Rothschild Holding S.A. purchased a new stake in shares of Biogen Inc. (NASDAQ:BIIB) during the second quarter, HoldingsChannel.com reports. The institutional investor purchased 56,064 shares of the biotechnology company’s stock, valued at approximately $12,113,000.

Several other institutional investors also recently modified their holdings of the business. Tocqueville Asset Management L.P. bought a new stake in Biogen in the 2nd quarter worth about $969,000. Mmbg Investment Advisors CO. bought a new position in Biogen during the 2nd quarter valued at about $270,000. Great Lakes Advisors LLC purchased a new stake in shares of Biogen during the 2nd quarter valued at about $2,048,000. Danske Bank A S purchased a new stake in shares of Biogen during the 2nd quarter valued at about $14,339,000. Finally, Wealthfront Advisers LLC bought a new stake in shares of Biogen in the second quarter worth approximately $3,571,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Up 4.2%

BIIB opened at $221.56 on Thursday. The firm’s 50 day simple moving average is $204.91 and its two-hundred day simple moving average is $194.08. The company has a market capitalization of $32.74 billion, a PE ratio of 39.21, a PEG ratio of 6.62 and a beta of 0.17. Biogen Inc. has a 1-year low of $131.52 and a 1-year high of $222.15. The company has a current ratio of 1.87, a quick ratio of 1.26 and a debt-to-equity ratio of 0.39.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $3.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.94 by $0.66. The firm had revenue of $2.74 billion during the quarter, compared to the consensus estimate of $2.46 billion. Biogen had a net margin of 8.32% and a return on equity of 11.18%. The company’s revenue for the quarter was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.47 EPS. Biogen has set its FY 2026 guidance at 12.000-13.000 EPS. As a group, equities analysts forecast that Biogen Inc. will post 12.39 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on BIIB shares. Oppenheimer reissued an “outperform” rating and set a $300.00 price objective on shares of Biogen in a report on Wednesday, July 29th. Rothschild & Co Redburn raised their target price on shares of Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. Freedom Capital raised shares of Biogen from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 1st. Morgan Stanley boosted their target price on shares of Biogen from $222.00 to $231.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Finally, HC Wainwright increased their price target on Biogen from $237.00 to $251.00 and gave the company a “buy” rating in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating, thirteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $227.07.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.